Top-News

Sophia Genetics Aktie News

Aktie
WKN:  A3CVT8 ISIN:  CH1125843347 US-Symbol:  SOPH Branche:  Gesundheitswesen: Anbieter u. Dienstleister Land:  Schweiz
4,855 $
-0,165 $
-3,29%
4,1696 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
255,28 Mio. €
Streubesitz
43,54%
KGV
-3,28
Index-Zuordnung
-

Sophia Genetics News

06.05.25 - PR Newswire
SOPHiA GENETICS Reports First Quarter 2025 Results
SOPHiA GENETICS Reports First Quarter 2025 Results PR Newswire
28.04.25 - PR Newswire
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR PR Newswire
28.04.25 - PR Newswire
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR PR Newswire
22.04.25 - PR Newswire
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 PR Newswire
08.04.25 - PR Newswire
Precision for Medicine geht mit SOPHiA GENETICS eine Partnerschaft ein, um seine Biopharma-Dienstleistungen mit der SOPHiA DDM™-Plattform und ihren Liquid-Biopsy-Funktionen zu erweitern
Precision for Medicine geht mit SOPHiA GENETICS eine Partnerschaft ein, um seine Biopharma-​Dienstleistungen mit der SOPHiA DDM™-Plattform und ihren Liquid-​Biopsy-...
08.04.25 - PR Newswire
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities PR Newswire
08.04.25 - PR Newswire
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities PR Newswire
18.03.25 - PR Newswire
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-​Driven Medicine at NVIDIA GTC PR Newswire
18.03.25 - PR Newswire
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-​Driven Medicine at NVIDIA GTC PR Newswire
04.03.25 - PR Newswire
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results PR Newswire
24.02.25 - PR Newswire
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
Leading Healthcare Institutions Adopt MSK-​ACCESS® for Liquid Biopsy Testing PR Newswire
18.02.25 - PR Newswire
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 PR Newswire
28.01.25 - PR Newswire
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities PR Newswire
28.01.25 - PR Newswire
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »